Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800712 | 0.89 | ALDH1A1 (0.78) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL2716970 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL374227 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL10826462 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL1126241 | 0.83 | KDM4E (0.71) | ALDH1A1KDM4ETDP1MAPK1SMN1; SMN2 | |
| SCHEMBL922597 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL922442 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL3568406 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL28215819 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL5578769 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4ETDP1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103121972-B | As the pyrimidine urea derivatives of kinase inhibitor | NOVARTIS AG (CH) | 2015-07-29 | — | — | CN | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| CN-103121973-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG | 2013-05-29 | — | — | CN | disclosed |
| CN-103121972-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG | 2013-05-29 | — | — | CN | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | ALDH1A1 4714/4885KDM4E 1982/4885TDP1 4673/4885 |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | ALDH1A1 4285/4885KDM4E 1074/4885TDP1 915/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | ALDH1A1 4285/4885KDM4E 1074/4885TDP1 915/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | ALDH1A1 4285/4885KDM4E 1074/4885TDP1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.